Quick Answer
NeuroPace Inc reported R&D Expense of $27.89 million for fiscal year 2025.
NeuroPace Inc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $27.89M | +17.9% |
| 2024 | $23.65M | +13.8% |
| 2023 | $20.78M | -5.3% |
| 2022 | $21.95M | +20.5% |
| 2021 | $18.21M | +16.0% |
| 2020 | $15.70M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.58M | +14.3% | -3.9% |
| June 30, 2025 | $6.84M | +12.9% | -8.0% |
| March 31, 2025 | $7.44M | +28.6% | +29.3% |
| September 30, 2024 | $5.75M | +20.0% | -5.1% |
| June 30, 2024 | $6.07M | +13.5% | +4.9% |
| March 31, 2024 | $5.78M | +9.9% | +20.6% |
| September 30, 2023 | $4.79M | -14.5% | -10.3% |
| June 30, 2023 | $5.34M | -5.8% | +1.5% |
- NeuroPace Inc showed an increase of +17.9% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, NeuroPace Inc’s r&d expense has grown by 77.7% (from $15.70 million to $27.89 million).
- The most recent figure is from NeuroPace Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: